184 related articles for article (PubMed ID: 30341616)
1. Methods to Screen Compounds Against Mutant p53 Misfolding and Aggregation for Cancer Therapeutics.
Ferretti GDDS; da Costa DCF; L Silva J; Pereira Rangel L
Methods Mol Biol; 2019; 1873():265-277. PubMed ID: 30341616
[TBL] [Abstract][Full Text] [Related]
2. The Lys-Specific Molecular Tweezer, CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.
Herzog G; Shmueli MD; Levy L; Engel L; Gazit E; Klärner FG; Schrader T; Bitan G; Segal D
Biochemistry; 2015 Jun; 54(24):3729-38. PubMed ID: 26030124
[TBL] [Abstract][Full Text] [Related]
3. Polyarginine and its analogues inhibit p53 mutant aggregation and cancer cell proliferation in vitro.
Chen Z; Chen J; Keshamouni VG; Kanapathipillai M
Biochem Biophys Res Commun; 2017 Jul; 489(2):130-134. PubMed ID: 28536076
[TBL] [Abstract][Full Text] [Related]
4. Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding.
Babikir HA; Afjei R; Paulmurugan R; Massoud TF
Cancer Treat Rev; 2018 Dec; 71():19-31. PubMed ID: 30336366
[TBL] [Abstract][Full Text] [Related]
5. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
[TBL] [Abstract][Full Text] [Related]
6. Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding.
Wang G; Fersht AR
Proc Natl Acad Sci U S A; 2015 Feb; 112(8):2443-8. PubMed ID: 25675527
[TBL] [Abstract][Full Text] [Related]
7. Prion-like p53 Amyloids in Cancer.
Navalkar A; Ghosh S; Pandey S; Paul A; Datta D; Maji SK
Biochemistry; 2020 Jan; 59(2):146-155. PubMed ID: 31603660
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p53 Mutant Peptide Aggregation In Vitro by Cationic Osmolyte Acetylcholine Chloride.
Chen Z; Kanapathipillai M
Protein Pept Lett; 2017; 24(4):353-357. PubMed ID: 28117010
[TBL] [Abstract][Full Text] [Related]
10. Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm.
Bauer MR; Krämer A; Settanni G; Jones RN; Ni X; Khan Tareque R; Fersht AR; Spencer J; Joerger AC
ACS Chem Biol; 2020 Mar; 15(3):657-668. PubMed ID: 31990523
[TBL] [Abstract][Full Text] [Related]
11. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
12. The Status of p53 Oligomeric and Aggregation States in Cancer.
de Oliveira GAP; Petronilho EC; Pedrote MM; Marques MA; Vieira TCRG; Cino EA; Silva JL
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32260447
[TBL] [Abstract][Full Text] [Related]
13. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.
Palanikumar L; Karpauskaite L; Al-Sayegh M; Chehade I; Alam M; Hassan S; Maity D; Ali L; Kalmouni M; Hunashal Y; Ahmed J; Houhou T; Karapetyan S; Falls Z; Samudrala R; Pasricha R; Esposito G; Afzal AJ; Hamilton AD; Kumar S; Magzoub M
Nat Commun; 2021 Jun; 12(1):3962. PubMed ID: 34172723
[TBL] [Abstract][Full Text] [Related]
14. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
15. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y
Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819
[TBL] [Abstract][Full Text] [Related]
17. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines.
Baud MGJ; Bauer MR; Verduci L; Dingler FA; Patel KJ; Horil Roy D; Joerger AC; Fersht AR
Eur J Med Chem; 2018 May; 152():101-114. PubMed ID: 29702446
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
19. Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells.
Melo Dos Santos N; de Oliveira GAP; Ramos Rocha M; Pedrote MM; Diniz da Silva Ferretti G; Pereira Rangel L; Morgado-Diaz JA; Silva JL; Rodrigues Pereira Gimba E
J Biol Chem; 2019 Jun; 294(24):9430-9439. PubMed ID: 31028175
[TBL] [Abstract][Full Text] [Related]
20. p53 protein aggregation promotes platinum resistance in ovarian cancer.
Yang-Hartwich Y; Soteras MG; Lin ZP; Holmberg J; Sumi N; Craveiro V; Liang M; Romanoff E; Bingham J; Garofalo F; Alvero A; Mor G
Oncogene; 2015 Jul; 34(27):3605-16. PubMed ID: 25263447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
